Global Gonorrhea Testing Market

Gonorrhea Testing Comprehensive Study by Test (Nucleic Acid Amplification (NAA), Gram Stain, Enzyme-linked immunosorbent assay (ELISA), Gonorrhea Culture, Rapid test), Sample (Blood, Lymph fluid, Urine, Throat swab, Penis/vaginal swab), End User (Hospitals, Pathology lab, Point of care testing) Players and Region - Global Market Outlook to 2030

Gonorrhea Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gonorrhea Testing
Gonorrhea is one of the very common sexually transmitted disease, which is basically an inflammation on mucous membrane surface caused by microorganism Neisseria gonorrhoeae. The infection can affect both women and men. In women, the infection grows in moist & warmth area of the reproductive tract including cervix, uterus, and fallopian tube. The infection also grows in throat, mouth, urethra, and anus, in both men and women. Most of the times, several men and women do not develop any noticeable symptoms of gonorrhea. Whenever the infected person develops any symptoms, it tends to be just like the other bacterial infection that makes it tough to identify the gonorrhea infection. Few of the gentle symptoms of gonorrhea include discharge from vagina and penis, frequent urine discharge, burning sensation whereas urinating, and fewer usually swollen testicles. The gonorrhea infection can spread through intercourse and oral or anal sex. In around 90 % of oral infection, there is no visible infection excluding sore throat, itchiness that is most common in any other bacterial infection.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Gonorrhea Testing market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Gonorrhea Testing market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gonorrhea Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Bayer AG (Germany), Merck and Company Inc. (United States), Agilent Technologies (United States), Biomerieux (France), Danaher Corporation (United States), Thermo Fisher Scientific (United States), Alere Inc. (United States), DiaSorin (Italy), Bristol-Myers Squibb (United States) and F. Hoffmann-La Roche AG. (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Gonorrhea Testing market by and Region.



On the basis of geography, the market of Gonorrhea Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Test, the sub-segment i.e. Nucleic Acid Amplification (NAA) will boost the Gonorrhea Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sample, the sub-segment i.e. Blood will boost the Gonorrhea Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Gonorrhea Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Increasing Involvement of Multiple Sex Partners, Changing Lifestyle across the Globe, High Awareness among the People With Respect To Sexually Transmitted Diseases and The existence of a Large Number of Point Of Care Tests

Challenges:
A High Cost Associated With the Gonorrhea Diagnostic Test

Restraints:
Reluctant Attitude of Patients towards the Diagnosis and Medication Couples with the Discontinuation of Assigned Therapies

Opportunities:
Emerging Demand from Economies

Market Leaders and their expansionary development strategies
In December 2023, Home testing firm Imaware announced that it has acquired Binx Health's at-home consumer testing business for an undisclosed amount. The acquisition is intended to expand Imaware's position in the home health testing market and broaden the number of enterprise clients serviced by Imaware.
In April 2019, Quest Diagnostics, the world's leading provider of diagnostic information services, launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion.


Key Target Audience
Gonorrhea Testing Companies, Gonorrhea Testing Components Manufacturers, Distributors, Importer/Exporter, Industry Associations, Regulatory & Government Bodies and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Test
  • Nucleic Acid Amplification (NAA)
  • Gram Stain
  • Enzyme-linked immunosorbent assay (ELISA)
  • Gonorrhea Culture
  • Rapid test

By Sample
  • Blood
  • Lymph fluid
  • Urine
  • Throat swab
  • Penis/vaginal swab

By End User
  • Hospitals
  • Pathology lab
  • Point of care testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Involvement of Multiple Sex Partners
      • 3.2.2. Changing Lifestyle across the Globe
      • 3.2.3. High Awareness among the People With Respect To Sexually Transmitted Diseases
      • 3.2.4. The existence of a Large Number of Point Of Care Tests
    • 3.3. Market Challenges
      • 3.3.1. A High Cost Associated With the Gonorrhea Diagnostic Test
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gonorrhea Testing, by Test, Sample, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gonorrhea Testing (Value)
      • 5.2.1. Global Gonorrhea Testing by: Test (Value)
        • 5.2.1.1. Nucleic Acid Amplification (NAA)
        • 5.2.1.2. Gram Stain
        • 5.2.1.3. Enzyme-linked immunosorbent assay (ELISA)
        • 5.2.1.4. Gonorrhea Culture
        • 5.2.1.5. Rapid test
      • 5.2.2. Global Gonorrhea Testing by: Sample (Value)
        • 5.2.2.1. Blood
        • 5.2.2.2. Lymph fluid
        • 5.2.2.3. Urine
        • 5.2.2.4. Throat swab
        • 5.2.2.5. Penis/vaginal swab
      • 5.2.3. Global Gonorrhea Testing by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Pathology lab
        • 5.2.3.3. Point of care testing
      • 5.2.4. Global Gonorrhea Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gonorrhea Testing (Price)
  • 6. Gonorrhea Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck and Company Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biomerieux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Danaher Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Thermo Fisher Scientific (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alere Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DiaSorin (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. F. Hoffmann-La Roche AG. (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Gonorrhea Testing Sale, by Test, Sample, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gonorrhea Testing (Value)
      • 7.2.1. Global Gonorrhea Testing by: Test (Value)
        • 7.2.1.1. Nucleic Acid Amplification (NAA)
        • 7.2.1.2. Gram Stain
        • 7.2.1.3. Enzyme-linked immunosorbent assay (ELISA)
        • 7.2.1.4. Gonorrhea Culture
        • 7.2.1.5. Rapid test
      • 7.2.2. Global Gonorrhea Testing by: Sample (Value)
        • 7.2.2.1. Blood
        • 7.2.2.2. Lymph fluid
        • 7.2.2.3. Urine
        • 7.2.2.4. Throat swab
        • 7.2.2.5. Penis/vaginal swab
      • 7.2.3. Global Gonorrhea Testing by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Pathology lab
        • 7.2.3.3. Point of care testing
      • 7.2.4. Global Gonorrhea Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gonorrhea Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gonorrhea Testing: by Test(USD Million)
  • Table 2. Gonorrhea Testing Nucleic Acid Amplification (NAA) , by Region USD Million (2018-2023)
  • Table 3. Gonorrhea Testing Gram Stain , by Region USD Million (2018-2023)
  • Table 4. Gonorrhea Testing Enzyme-linked immunosorbent assay (ELISA) , by Region USD Million (2018-2023)
  • Table 5. Gonorrhea Testing Gonorrhea Culture , by Region USD Million (2018-2023)
  • Table 6. Gonorrhea Testing Rapid test , by Region USD Million (2018-2023)
  • Table 7. Gonorrhea Testing: by Sample(USD Million)
  • Table 8. Gonorrhea Testing Blood , by Region USD Million (2018-2023)
  • Table 9. Gonorrhea Testing Lymph fluid , by Region USD Million (2018-2023)
  • Table 10. Gonorrhea Testing Urine , by Region USD Million (2018-2023)
  • Table 11. Gonorrhea Testing Throat swab , by Region USD Million (2018-2023)
  • Table 12. Gonorrhea Testing Penis/vaginal swab , by Region USD Million (2018-2023)
  • Table 13. Gonorrhea Testing: by End User(USD Million)
  • Table 14. Gonorrhea Testing Hospitals , by Region USD Million (2018-2023)
  • Table 15. Gonorrhea Testing Pathology lab , by Region USD Million (2018-2023)
  • Table 16. Gonorrhea Testing Point of care testing , by Region USD Million (2018-2023)
  • Table 17. South America Gonorrhea Testing, by Country USD Million (2018-2023)
  • Table 18. South America Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 19. South America Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 20. South America Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 21. Brazil Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 22. Brazil Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 23. Brazil Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 24. Argentina Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 25. Argentina Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 26. Argentina Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 27. Rest of South America Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 28. Rest of South America Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 29. Rest of South America Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 30. Asia Pacific Gonorrhea Testing, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 32. Asia Pacific Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 33. Asia Pacific Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 34. China Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 35. China Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 36. China Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 37. Japan Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 38. Japan Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 39. Japan Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 40. India Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 41. India Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 42. India Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 43. South Korea Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 44. South Korea Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 45. South Korea Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 46. Taiwan Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 47. Taiwan Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 48. Taiwan Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 49. Australia Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 50. Australia Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 51. Australia Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 55. Europe Gonorrhea Testing, by Country USD Million (2018-2023)
  • Table 56. Europe Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 57. Europe Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 58. Europe Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 59. Germany Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 60. Germany Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 61. Germany Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 62. France Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 63. France Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 64. France Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 65. Italy Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 66. Italy Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 67. Italy Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 68. United Kingdom Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 69. United Kingdom Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 70. United Kingdom Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 71. Netherlands Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 72. Netherlands Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 73. Netherlands Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 74. Rest of Europe Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 75. Rest of Europe Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 76. Rest of Europe Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 77. MEA Gonorrhea Testing, by Country USD Million (2018-2023)
  • Table 78. MEA Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 79. MEA Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 80. MEA Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 81. Middle East Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 82. Middle East Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 83. Middle East Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 84. Africa Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 85. Africa Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 86. Africa Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 87. North America Gonorrhea Testing, by Country USD Million (2018-2023)
  • Table 88. North America Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 89. North America Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 90. North America Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 91. United States Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 92. United States Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 93. United States Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 94. Canada Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 95. Canada Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 96. Canada Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 97. Mexico Gonorrhea Testing, by Test USD Million (2018-2023)
  • Table 98. Mexico Gonorrhea Testing, by Sample USD Million (2018-2023)
  • Table 99. Mexico Gonorrhea Testing, by End User USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Gonorrhea Testing: by Test(USD Million)
  • Table 112. Gonorrhea Testing Nucleic Acid Amplification (NAA) , by Region USD Million (2025-2030)
  • Table 113. Gonorrhea Testing Gram Stain , by Region USD Million (2025-2030)
  • Table 114. Gonorrhea Testing Enzyme-linked immunosorbent assay (ELISA) , by Region USD Million (2025-2030)
  • Table 115. Gonorrhea Testing Gonorrhea Culture , by Region USD Million (2025-2030)
  • Table 116. Gonorrhea Testing Rapid test , by Region USD Million (2025-2030)
  • Table 117. Gonorrhea Testing: by Sample(USD Million)
  • Table 118. Gonorrhea Testing Blood , by Region USD Million (2025-2030)
  • Table 119. Gonorrhea Testing Lymph fluid , by Region USD Million (2025-2030)
  • Table 120. Gonorrhea Testing Urine , by Region USD Million (2025-2030)
  • Table 121. Gonorrhea Testing Throat swab , by Region USD Million (2025-2030)
  • Table 122. Gonorrhea Testing Penis/vaginal swab , by Region USD Million (2025-2030)
  • Table 123. Gonorrhea Testing: by End User(USD Million)
  • Table 124. Gonorrhea Testing Hospitals , by Region USD Million (2025-2030)
  • Table 125. Gonorrhea Testing Pathology lab , by Region USD Million (2025-2030)
  • Table 126. Gonorrhea Testing Point of care testing , by Region USD Million (2025-2030)
  • Table 127. South America Gonorrhea Testing, by Country USD Million (2025-2030)
  • Table 128. South America Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 129. South America Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 130. South America Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 131. Brazil Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 132. Brazil Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 133. Brazil Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 134. Argentina Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 135. Argentina Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 136. Argentina Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 137. Rest of South America Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 138. Rest of South America Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 139. Rest of South America Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 140. Asia Pacific Gonorrhea Testing, by Country USD Million (2025-2030)
  • Table 141. Asia Pacific Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 142. Asia Pacific Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 143. Asia Pacific Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 144. China Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 145. China Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 146. China Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 147. Japan Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 148. Japan Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 149. Japan Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 150. India Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 151. India Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 152. India Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 153. South Korea Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 154. South Korea Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 155. South Korea Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 156. Taiwan Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 157. Taiwan Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 158. Taiwan Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 159. Australia Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 160. Australia Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 161. Australia Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 164. Rest of Asia-Pacific Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 165. Europe Gonorrhea Testing, by Country USD Million (2025-2030)
  • Table 166. Europe Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 167. Europe Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 168. Europe Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 169. Germany Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 170. Germany Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 171. Germany Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 172. France Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 173. France Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 174. France Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 175. Italy Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 176. Italy Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 177. Italy Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 178. United Kingdom Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 179. United Kingdom Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 180. United Kingdom Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 181. Netherlands Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 182. Netherlands Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 183. Netherlands Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 184. Rest of Europe Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 185. Rest of Europe Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 186. Rest of Europe Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 187. MEA Gonorrhea Testing, by Country USD Million (2025-2030)
  • Table 188. MEA Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 189. MEA Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 190. MEA Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 191. Middle East Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 192. Middle East Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 193. Middle East Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 194. Africa Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 195. Africa Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 196. Africa Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 197. North America Gonorrhea Testing, by Country USD Million (2025-2030)
  • Table 198. North America Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 199. North America Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 200. North America Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 201. United States Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 202. United States Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 203. United States Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 204. Canada Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 205. Canada Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 206. Canada Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 207. Mexico Gonorrhea Testing, by Test USD Million (2025-2030)
  • Table 208. Mexico Gonorrhea Testing, by Sample USD Million (2025-2030)
  • Table 209. Mexico Gonorrhea Testing, by End User USD Million (2025-2030)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gonorrhea Testing: by Test USD Million (2018-2023)
  • Figure 5. Global Gonorrhea Testing: by Sample USD Million (2018-2023)
  • Figure 6. Global Gonorrhea Testing: by End User USD Million (2018-2023)
  • Figure 7. South America Gonorrhea Testing Share (%), by Country
  • Figure 8. Asia Pacific Gonorrhea Testing Share (%), by Country
  • Figure 9. Europe Gonorrhea Testing Share (%), by Country
  • Figure 10. MEA Gonorrhea Testing Share (%), by Country
  • Figure 11. North America Gonorrhea Testing Share (%), by Country
  • Figure 12. Global Gonorrhea Testing share by Players 2023 (%)
  • Figure 13. Global Gonorrhea Testing share by Players (Top 3) 2023(%)
  • Figure 14. Global Gonorrhea Testing share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 20. Merck and Company Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck and Company Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 23. Agilent Technologies (United States) Revenue: by Geography 2023
  • Figure 24. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 25. Biomerieux (France) Revenue: by Geography 2023
  • Figure 26. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 28. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 29. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 30. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Alere Inc. (United States) Revenue: by Geography 2023
  • Figure 32. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 33. DiaSorin (Italy) Revenue: by Geography 2023
  • Figure 34. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 36. F. Hoffmann-La Roche AG. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. F. Hoffmann-La Roche AG. (Switzerland) Revenue: by Geography 2023
  • Figure 38. Global Gonorrhea Testing: by Test USD Million (2025-2030)
  • Figure 39. Global Gonorrhea Testing: by Sample USD Million (2025-2030)
  • Figure 40. Global Gonorrhea Testing: by End User USD Million (2025-2030)
  • Figure 41. South America Gonorrhea Testing Share (%), by Country
  • Figure 42. Asia Pacific Gonorrhea Testing Share (%), by Country
  • Figure 43. Europe Gonorrhea Testing Share (%), by Country
  • Figure 44. MEA Gonorrhea Testing Share (%), by Country
  • Figure 45. North America Gonorrhea Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Merck and Company Inc. (United States)
  • Agilent Technologies (United States)
  • Biomerieux (France)
  • Danaher Corporation (United States)
  • Thermo Fisher Scientific (United States)
  • Alere Inc. (United States)
  • DiaSorin (Italy)
  • Bristol-Myers Squibb (United States)
  • F. Hoffmann-La Roche AG. (Switzerland)
Select User Access Type

Key Highlights of Report


Feb 2024 150 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gonorrhea Testing Market Quantitative research analysis
Global Gonorrhea Testing Market Qualitative Industry Analysis
Global Gonorrhea Testing Market Quantitative research analysis
Global Gonorrhea Testing Market Qualitative Industry Analysis
Global Gonorrhea Testing Market Quantitative research analysis
Global Gonorrhea Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Bayer AG (Germany), Merck and Company Inc. (United States), Agilent Technologies (United States), Biomerieux (France), Danaher Corporation (United States), Thermo Fisher Scientific (United States), Alere Inc. (United States), DiaSorin (Italy), Bristol-Myers Squibb (United States) and F. Hoffmann-La Roche AG. (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Gonorrhea Testing Market during projected period 2023-2030.
The Gonorrhea Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gonorrhea Testing Market Report?

Have a Query? Click Here

Other Related Reports

Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500
Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350
Cervical Cancer Comprehensive Study by Type (Squamous cell carcinoma, Adenocarcinoma), Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug Type (Avastin (Bev...
$ 3750
Wound Care Treatments Comprehensive Study by Type (Surgical Wound Care Products, Advanced Wound Care Products, Traditional Wound Care Products), Application (Hospitals, Clinics, Home Care, Others), W...
$ 3350
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500
Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350
Cervical Cancer Comprehensive Study by Type (Squamous cell carcinoma, Adenocarcinoma), Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug Type (Avastin (Bev...
$ 3750
Wound Care Treatments Comprehensive Study by Type (Surgical Wound Care Products, Advanced Wound Care Products, Traditional Wound Care Products), Application (Hospitals, Clinics, Home Care, Others), W...
$ 3350
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500
Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350
Cervical Cancer Comprehensive Study by Type (Squamous cell carcinoma, Adenocarcinoma), Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug Type (Avastin (Bev...
$ 3750